Kamada completes Russia rabies vaccine registration

Israel's GDP jumps but still below pre-war level

The company is now working to begin sales in Russia as early as the first half of 2011.

Drug developer Kamada Ltd. (TASE: KMDA) reported this morning that it completed the process of registering its passive rabies vaccine in Russia.

The company is now working to begin sales in Russia as early as the first half of 2011.

The vaccine is derived from human plasma with additional antibodies, and is used to prevent rabies, which affects the central nervous system.

Kamada will market the vaccine in Russia under the trade name Rebinolin.

It is estimated that the global market for a passive vaccine against rabies is around $100 million per year.

Published by Globes [online], Israel business news - www.globes-online.com - on September 13, 2010

The company is now working to begin sales in Russia as early as the first half of 2011.